The study presents [18F]ACI 19278 and [18F]ACI 19626, small molecule PET tracers that target pathological TDP 43 inclusions across FTLD TDP, ALS, and LATE tissue. Both ligands show excellent selectivity over common co pathologies and favorable brain pharmacokinetics in non human primates.
Researchers from the DQBM Polymenidou Lab contributed to the work, with DQBM authors listed among the affiliations and in the study contributions. ACI 19626 was selected as the lead candidate for first in human testing.